Exploring the Potential of Therapeutic Plasma...

Albumin is one of those topics where everyone has an opinion, but very few people actually look at the cost-benefit data. In this lecture, I’m breaking down why the 5% albumin you’re hanging might be a waste of money, and where the 25% concentration actually moves the needle in s ...  Show more

A new prospective multicenter cohort of 250 patients with shock examines the safety and outcomes of peripheral vasopressor administration. Extravasation events were rare and clustered only after several days of infusion, while norepinephrine use and simple physiologic markers cor ...  Show more

In this JACC Deep Dive, Editor-in-Chief Harlan M. Krumholz, MD, SM, discusses a large real-world study by Min et al. examining heart failure with improved ejection fraction (HFimpEF) in over 24,000 patients. The study found that while EF improvement is common (30%), true remissio ...  Show more

Join Dr. Jerry Yoo as he sits down with Dr. Tom Buchheit, Director of the Regenerative Pain Therapies Program at Duke University. In this episode, Dr. Buchheit shares insights into how regenerative medicine and regenerative physical therapy can potentially spare individuals f ...

In this episode, we have the honor of speaking with Professor John Myburgh, a former South African physician and researcher who has dedicated his life to improving the field of critical care medicine. Professor Myburgh has made significant contributions to the field of fluid resu ...  Show more

Joseph Mikhael, MD, and Krina K. Patel, MD, MSc, discuss considerations for CAR T-Cell therapy in multiple myeloma, including age, access, and bridging therapy. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002715. ...  Show more